“Pre-exposure prophylaxis (PrEP) was supposed to usher in an end to the HIV epidemic. Now, seven years after its approval, it’s clear that the once-daily pill has failed to reach the very patients who need it most.
For veteran HIV researcher Michael Saag, M.D., with the University of Alabama at Birmingham, the reason is simple: PrEP is too expensive.
In a blistering speech at the 2019 National HIV Prevention Conference (NHPC) in Atlanta, Saag argued that the $1,600 per month cost of the HIV prevention pill is the single largest barrier to widespread uptake in the United States.”
For more, click here.